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Core evidence outcomes summary for Exubera (inhaled insulin) in the management of type 1 and type 2 diabetes

  **Outcome measure**                                              **Evidence**   **Implications**
  ---------------------------------------------------------------- -------------- ------------------------------------------------------------------------------
  **Patient-oriented evidence**                                                   
  Improved patient satisfaction                                    Clear          Improved preference for Exubera compared with subcutaneous insulin
  No significant weight gain                                       Clear          Similar to or less than subcutaneous insulin
  Improvement in quality of life                                   Moderate       Improved quality of life with Exubera compared with subcutaneous insulin
  **Disease-oriented evidence**                                                   
  Effective glycemic control -- reduction in HbA~1c~ levels        Clear          Exubera is as effective as subcutaneous insulin
  Incidence of hypoglycemia                                        Moderate       Similar to subcutaneous insulin
  Reduction in pulmonary function                                  Limited        No clinically relevant effect in short term; long-term studies not published
  **Economic evidence**                                                           
  Cost effectiveness in patients with type 1 and type 2 diabetes   No evidence    Remains to be determined

Scope, aims, and objectives
===========================

Effective glycemic control is associated with a reduced risk of microvascular and macrovascular complications in patients with diabetes. The inconvenience and poor patient acceptability of intensive insulin regimens, which may require several injections per day, has contributed to poor glycemic control in patients with type 1 or type 2 diabetes. Therefore, alternative routes of insulin administration to achieve and maintain optimal glycemic control have been investigated. A dry-powder insulin has been developed for the pulmonary delivery of insulin by an aerosol device (Exubera^®^). The objective of this article is to review the current evidence for this insulin delivery system in the clinical management of type 1 and type 2 diabetes. To distinguish this insulin delivery system from others being developed, it is referred to as Exubera throughout.

Methods
=======

Literature searches were conducted on January 17--26, 2005, in the following databases using the search terms "Exubera," "pulmonary insulin," OR "inhaled insulin." The cut-off date was from the beginning of the database to the date of the search unless otherwise stated: PubMed, <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi>, 1966 to date. Search strategy: "Exubera OR inhaled insulin" limited to English-language results onlyEMBASE, <http://www.datastarweb.com>, 1974 to date. Search strategy: "Exubera OR inhaled insulin" limited to English-language results onlyDatabase of Abstracts of Reviews of Effectiveness (DARE), NHS Economic Evaluations Database (NHSEED), Health Technology Assessment (HTA), [www.york.ac.uk/inst/crd/darehp.htm](www.york.ac.uk/inst/crd/darehp.htm). All three databases were searched together. All fields searchedNational Guideline Clearing House, [www.guideline.gov](www.guideline.gov)National Institute for Health and Clinical Excellence (NICE), [www.nice.org.uk](www.nice.org.uk)Cochrane Database of Systematic Reviews (CDSR), [www.cochrane.org/index0.htm](www.cochrane.org/index0.htm). Entire site searched

After removal of duplicates, a total of 206 records were retrieved, one from DARE and the remainder from PubMed or EMBASE. Clinical guidelines were also identified from NICE, the European Diabetes Policy Group (EDPG), and the American Diabetes Association (ADA). Records were manually reviewed and any animal studies, *in-vitro* studies, news articles, general narrative reviews, or articles which mentioned Exubera but did not discuss clinical trial data were excluded. The remaining 11 records were included.

Any identified systematic reviews (including meta analyses), randomized controlled trials (RCTs), and relevant case studies were then classified into five classes of evidence based on the design of the study, with level 1 evidence representing the strongest level of evidence and level 5 representing the weakest evidence as summarized in [Table 1](#t1-ce-1-089){ref-type="table"}. One systematic review was identified. All other articles were of level 2 or level 3 evidence reported as full publications. Publications relating to pharmacoeconomic evidence with Exubera were not identified.

Thirty-five abstracts from ADA meetings and European Association for the Study of Diabetes (EASD) meetings (1998--2003) were identified from a systematic review of these sources. Twenty-three abstracts were excluded because they were animal studies (n=1) or were abstracts that duplicated results from studies which have since been published in full (n=22). One abstract (level 3 evidence) which detailed results from a pooled analysis of two multicenter randomized controlled phase II trials in patients with type 1 and type 2 diabetes was also excluded due to the availability of significant level 2 evidence ([@b13-ce-1-089]).

Abstracts from the 64th Scientific Sessions of the [@b2-ce-1-089] and the 40th EASD Meeting 2004 were also searched electronically on January 26--27, 2005, using the search terms "Exubera" OR "inhaled insulin." This yielded 15 records, of which four were excluded for the following reasons: animal studies (n=2), duplicate publication of data presented in full papers (n=2) ([Table 1](#t1-ce-1-089){ref-type="table"}). All abstracts were of level 2 evidence.

The searches were updated on June 23, 2005. After excluding duplicates, a total of 12 new records were identified, of which nine were excluded for the following reasons: general narrative reviews (n=3), articles that did not mention Exubera (n=5), animal study (n=1). Three articles remained, and were included ([Table 1](#t1-ce-1-089){ref-type="table"}). Abstracts from the 65th Scientific Sessions of the ADA 2005 (<http://scientificsessions.diabetes.org>) were also searched electronically on June 29, 2005. This yielded 14 records, of which 11 were excluded for the following reasons: did not refer to Exubera (n=9), animal studies (n=2) ([Table 1](#t1-ce-1-089){ref-type="table"}). All abstracts were of level 2 evidence.

Disease overview
================

The diabetes epidemic
---------------------

It is estimated that there are currently approximately 194 million people with diabetes worldwide and the prevalence is projected to exceed 333 million by 2025 ([@b43-ce-1-089]). Type 1 diabetes may account for 5--10% of all diagnosed cases of diabetes and usually affects children and young adults, although onset may occur at any age ([@b3-ce-1-089]). In comparison, type 2 diabetes accounts for over 90% of diabetes cases and is associated with age, obesity, family history of diabetes, impaired glucose metabolism, physical inactivity, and race/ethnicity. The increasing prevalence of type 2 diabetes in children and adolescents is fast being recognized as a global health problem ([@b55-ce-1-089]).

Consequences of inadequate glycemic control
-------------------------------------------

A recent report by the American Association of Clinical Endocrinologists (AACE) highlighted that 67% of individuals with type 2 diabetes did not have adequately controlled blood glucose levels ([@b1-ce-1-089]). Uncontrolled diabetes may contribute to increased rates of macrovascular and microvascular diabetic complications. Indeed people with diabetes are two to four times more likely to develop cardiovascular disease and have a greater risk of heart attack or stroke than individuals without diabetes ([@b43-ce-1-089]). Diabetes is also the leading cause of end-stage renal disease, accounting for 44% of new cases and is the leading cause of blindness in the Western world ([@b15-ce-1-089]). These complications place a huge burden on healthcare services. It is estimated that the total direct and indirect expenditure for diabetes in the US alone in 2002 was \$US132 billion ([@b41-ce-1-089]). A recent meta analysis of prospective cohort studies in patients with diabetes has also suggested that hyperglycemia is associated with an increased risk of cardiovascular disease ([@b61-ce-1-089]).

The UK Prospective Diabetes Study (UKPDS) and the Diabetes Control and Complications Trial (DCCT) demonstrated that the risk of developing and the progression of microvascular complications are substantially reduced with intensive blood glucose control (HbA~1c~ approximately 7%) in both type 2 diabetes ([@b77-ce-1-089],[@b78-ce-1-089]) and type 1 diabetes ([@b22-ce-1-089]). In general, for every 1% reduction in HbA~1c~, the risk of developing microvascular diabetic complications is reduced by 40% ([@b15-ce-1-089]). The DCCT study showed that intensive insulin therapy (administration of insulin three or more times daily by injection or an external pump) decreased the frequency and severity of microvascular and neurologic complications compared to conventional insulin ([@b22-ce-1-089]). The occurrence of microalbuminuria was reduced by 39% and albuminuria and clinical neuropathy were reduced by 54% and 60%, respectively. However, this intensive therapy was associated with a two- to three-fold increase in severe hypoglycemia. Furthermore, the UKPDS 33 study demonstrated that weight gain was significantly higher (mean + 2.9 kg) in patients with type 2 diabetes receiving intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment with diet (*P*\<0.001) ([@b77-ce-1-089]). A further study in Japanese patients with type 2 diabetes demonstrated that intensive glycemic control by multiple insulin injection therapy delayed the onset and progression of diabetic retinopathy, nephropathy, and neuropathy more effectively than conventional insulin therapy ([@b52-ce-1-089]).

Current therapy options
=======================

Type 1 diabetes
---------------

Type 1 diabetes develops when the body's immune system destroys pancreatic beta cells and the individual is unable to produce insulin to control blood glucose levels. Therefore, it is essential that patients with type 1 diabetes receive insulin. Several types of human insulin and insulin analogs are currently available ([Table 2](#t2-ce-1-089){ref-type="table"}). Insulin may be delivered by subcutaneous, multiple injections via a syringe or a pen with needle and cartridge, or via an insulin pump ([@b2-ce-1-089]). Insulin pumps are small devices (about the size of a pager), containing a reservoir of rapid-acting insulin, which are programmed to deliver a constant flow of insulin into the patient via a needle or cannula.

Rapid-acting insulin analogs are generally injected with a meal and have a rapid onset and a short duration of action, so there is less chance of hypoglycemia. These are generally considered the most appropriate type of insulin for mealtime use. Short-acting insulins may also be used at mealtimes. However, their time to onset and duration of action is greater than that of the rapid-acting analogs. Long-acting insulins are the best options for basal control of blood glucose and are generally used in combination with either rapid-acting or short-acting insulin. Premixed insulins are also available which contain a combination of intermediate-acting and either rapid-acting or short-acting insulins. These premixed insulins are generally available as pre-filled insulin pens which improve the accuracy of insulin administration and adherence.

One of the major disadvantages of insulin use is the occurrence of hypoglycemia resulting from an imbalance of insulin use, and physical activity and/or calorie consumption.

Type 2 diabetes
---------------

Initially, patients with type 2 diabetes may be able to control their blood glucose levels with diet and exercise alone or with antihyperglycemic drug monotherapy. However, many patients will progress to require additional therapies (combination oral agents and/or insulin). Currently, there are several classes of oral antidiabetic medication available which may be used as a monotherapy or in combination ([Table 3](#t3-ce-1-089){ref-type="table"}). Most of the commonly used oral antidiabetics are only able to reduce HbA~1c~ by approximately 1%. This reduction is not sufficient for patients who have HbA~1c~ levels much greater than the recommended target. Furthermore, long-term glycemic control is difficult to sustain with oral antidiabetic agents and many patients additionally require insulin therapy.

New classes of noninsulin diabetic drugs have entered the market to address the need for long-term glycemic control in patients with type 2 diabetes. These include the glucagon-like peptide-1 (GLP-1) agonist exenatide (Byetta^®^), and a synthetic analog of human amylin called pramlintide acetate (Symlin^®^) which was approved by the Food and Drug Administration (FDA) in March 2005. The dipeptidyl peptidase-4 (DPP-4) inhibitors are also soon expected to enter the market.

### GLP-1 analogs

GLP-1 is an incretin hormone which is secreted from endocrine cells located in the intestinal mucosa, and acts to enhance meal-induced insulin secretion. GLP-1 analogs are injectable and it is expected that they will be used following the failure of oral antidiabetic agents in patients who are reluctant to use insulin. The GLP-1 analog exenatide is the first in a new class of diabetes treatment called incretin mimetics to be approved by the FDA (June 2005). It is approved as an adjunctive therapy in patients with type 2 diabetes who have not achieved adequate control on metformin and/or a sulfonylurea. Liraglutide, a long-acting derivative of GLP-1 which will be administered by injection once a day, is expected to be launched in 2007.

### DPP-4 inhibitors

The DPP-4 inhibitors inhibit the enzyme responsible for the breakdown of GLP-1 ([@b51-ce-1-089]). In animal studies, DPP-4 inhibitors have been reported to suppress DPP-4 activity by up to 90% and to delay the onset of hyperglycemia ([@b51-ce-1-089]). Several DPP-4 inhibitors are currently in development including LAF-237 (Novartis) and MK-431 (Merck) ([@b6-ce-1-089]). These inhibitors are currently in phase III trials and the launch of LAF-237 and MK-431 are expected in 2007 and 2009, respectively. In contrast to the GLP-1 analogs, these agents will be available as oral formulations which should increase patient acceptability and compliance.

Current treatment guidelines
----------------------------

Recent US, European, and UK guidelines for type 2 diabetes recommend glycemic targets with an HbA~1c~ target range below 6.5--7.5% ([@b27-ce-1-089]; [@b50-ce-1-089]; [@b5-ce-1-089]). The ADA guidelines also recommend considering a target of \<6% in individual patients ([@b5-ce-1-089]). The risks and benefits of HbA~1c~ levels below 6% are currently being evaluated by the ongoing Action to Control Cardiovascular Risk in Diabetes (ACCORD) study in patients with type 2 diabetes.

Current NICE guidelines (due to be reviewed in September 2005) recommend that insulin therapy should be offered to diabetic patients with inadequate blood glucose control receiving optimized oral antidiabetic agents ([@b50-ce-1-089]). Furthermore, EDPG guidelines recommend that insulin therapy is initiated when HbA~1c~ has deteriorated to \>7.5% after maximum attention to dietary control and oral glucose-lowering therapy ([@b27-ce-1-089]). An algorithm for the treatment of type 2 diabetes mellitus suggests that insulin should be reserved for patients who fail to adequately respond to a combination of oral antidiabetic agents ([@b48-ce-1-089]). However, [@b48-ce-1-089] suggest that prescribing decisions often appear to be made on subjective grounds such as familiarity with a particular drug which may explain regional differences in prescribing.

Unmet needs
===========

To avoid the development of complications and reduce morbidity and mortality in patients with diabetes, tight glycemic control is of great importance. Insulin therapy is central to the treatment of patients with type 1 diabetes. In contrast, the progressive decrease in beta-cell function in the pathogenesis of type 2 diabetes means that many patients will eventually fail on oral antidiabetic agents and will require insulin. It is well known in routine clinical practice that the majority of patients fail to achieve optimal glycemic control. Data from the National Health and Nutrition Examination Survey (NHANES) III demonstrated that from 1988 to 2000 a decrease in glycemic control was observed among US adults diagnosed with type 2 diabetes ([@b46-ce-1-089]). The proportion of patients with HbA~1c~ levels \<7% declined from 44.5% in the period 1988--1994 to 35.8% between 1999 and 2000. The use of insulin alone also decreased from 24.2% to 16.4% in these periods. There is reluctance by patients and physicians to treat type 2 diabetes with insulin despite its ability to achieve tight glycemic control. Healthcare providers often delay the initiation and intensification of insulin therapy in patients with type 2 diabetes until after the failure of multiple oral agents. This reluctance to initiate insulin therapy is partly due to the burden of multiple daily injections which are associated with poor patient compliance, particularly in those patients with a phobia of needles, and a fear of causing hypoglycemia or weight gain ([@b47-ce-1-089]). Therefore, alternative insulin delivery systems are required to improve patient and physician acceptability, adherence with insulin therapy, and thus improve the management of the disease. However, the mode of administration may not be the only issue. Many patients may perceive insulin per se as a "failure" in themselves or their health professional and that their diabetes is now "severe."

New methods for the delivery of insulin must balance improved patient acceptability, convenience and quality of life with achievement of therapeutic drug levels that are at least as effective as traditional subcutaneous formulations on diabetic outcomes such as blood glucose and HbA~1c~, without increasing the risk of hypoglycemic episodes or weight gain. It is expected that improved glucose control achieved by better adherence to insulin regimens will reduce the development of complications commonly associated with diabetes.

Advances in syringe and needle technology and the use of insulin pens and pumps have improved the accuracy and convenience of insulin administration. Despite the relative success of these devices, several different routes of administration have been investigated including the transdermal, intranasal, oral, buccal, and pulmonary routes ([@b53-ce-1-089]; [@b18-ce-1-089]). Limited success has been achieved with intranasal, oral, and transdermal insulin delivery. Due to the large size of the insulin molecule, nasal and transdermal delivery is inadequate and requires penetration enhancers which pose safety concerns ([@b53-ce-1-089]; [@b18-ce-1-089]). Therefore, these modes of delivery would be more suited to basal administration of insulin. Oral enteric insulin is broken down by digestive enzymes and has limited bioavailability ([@b18-ce-1-089]). A buccal system (Oralin) delivering a liquid formulation of insulin as a fine spray via the Generex Rapid Mist^™^ device has been developed by Generex Biotechnology. Limited data in patients with type 2 diabetes have demonstrated that Oralin may be used instead of meal-time insulin injections ([@b33-ce-1-089],[@b34-ce-1-089]).

The lungs have a large surface area, highly permeable membrane, and rich blood perfusion offering great potential for the delivery of polypeptide drugs such as insulin across the alveolar wall. Several inhaled insulin products have been successful in controlling blood glucose levels and three products are currently in phase III clinical trials ([Table 4](#t4-ce-1-089){ref-type="table"}). Comparisons between these inhaled insulin delivery systems are needed to determine the advantages and disadvantages of each system including their relative convenience and ease of use.

Of these different inhaled insulin products, Exubera is the furthest along in development. Exubera is a fine dry-powder (particle size 1--5 μm) insulin formulation jointly developed by Pfizer and Sanofi-Aventis Group. The insulin formulation developed by Nektar Therapeutics is packaged into blisters containing either 1 or 3 mg of insulin and made up to a total weight of 5 mg with mannitol, glycine, and sodium citrate. Higher doses are achieved with further inhalation of 1 or 3 mg blisters. Nektar Therapeutics developed both the insulin blisters and a hand-held inhaler device, which converts the powder particles into an aerosol cloud. This noninvasive, pulmonary inhalation system delivers insulin into the systemic circulation via the lung alveoli by transcytosis. No power source or propellants are used and the clear chamber ensures that the patient knows when all the insulin has been inhaled to allow accurate dosing. However, some patients may question the convenience of the chamber with regards to its portability.

The AERx^®^ iDMS delivery device includes a breath-guidance system that only delivers drug to the lung when breathing is correct ([@b49-ce-1-089]). This device also features a data-downloading system, facilitating the review of dose administration data and breathing technique. This provides clinicians with information about patient dosing regimens and compliance ([@b21-ce-1-089]). In comparison, the Technosphere insulin system used a commercially available asthma inhaler for the proof-of-concept study ([@b69-ce-1-089]).

Clinical evidence with Exubera
==============================

A number of patient- and disease-oriented outcomes have been evaluated with Exubera that reflect its potential role in the management of diabetes. Fundamentally, the formulation must demonstrate that therapeutic levels of insulin can be achieved, which have an effect on blood measures of glucose and which do not raise the risk of hypoglycemia. From a patient perspective, the formulation needs to be acceptable to patients and ideally more convenient than alternative methods of delivery.

Achievement of insulin levels
-----------------------------

Studies assessing the pharmacokinetics of Exubera in healthy volunteers and in patients with type 2 diabetes have shown that Exubera is rapidly absorbed, with insulin concentrations peaking earlier and decreasing more rapidly compared with subcutaneous regular insulin ([@b54-ce-1-089]). Furthermore, the onset of action (time to maximal effect) of Exubera has been shown to be at least as fast as the subcutaneously injected rapid-acting insulin analog insulin lispro in healthy volunteers (143 min versus 137 min) ([@b57-ce-1-089]). The duration of action, as determined by time to late half-maximal effect, was longer with Exubera than lispro (387 min versus 313 min). These characteristics suggest that Exubera provides an alternative therapy for meal-time glucose control.

Blood glucose control
---------------------

The efficacy of Exubera was primarily assessed by equivalence studies comparing glycemic control with subcutaneous insulin. Reduction in HbA~1c~ levels and the proportion of patients who met treatment guideline targets for HbA~1c~ (i.e. below 6.5--7.5%) were the main outcomes for efficacy.

Strong level 1 evidence from a systematic review of small, short-term, proof of concept phase II studies in patients with type 1 diabetes (3 studies) and type 2 diabetes (3 studies) showed similar HbA~1c~ reductions in patients randomized to inhaled insulin plus subcutaneous ultralente compared with a control group who received their former subcutaneous insulin regimen ([@b16-ce-1-089]; [@b65-ce-1-089]; [@b60-ce-1-089]). A further proof of concept superiority study also showed that glycemic control could be improved in insulin-naïve patients with type 2 diabetes and suboptimal glycemic control by the addition of Exubera to oral antidiabetic agents compared to oral antidiabetic monotherapy ([@b79-ce-1-089]).

These observations are supported by evidence from two open-label, randomized phase III clinical studies of 6 months' duration which demonstrates that Exubera provides glycemic control comparable to that with conventional insulin regimens in patients with type 1 diabetes ([@b56-ce-1-089]; [@b68-ce-1-089]) ([Table 5](#t5-ce-1-089){ref-type="table"}). Furthermore, a study in 226 patients with type 1 diabetes has shown that Exubera provides glycemic control similar to that of a subcutaneous short-acting insulin over a 12-week period ([@b25-ce-1-089]).

Results from three open-label, randomized, parallel-group, multicenter, phase III clinical trials in patients with type 2 diabetes have also demonstrated comparable reductions in HbA~1c~ between Exubera and conventional subcutaneous insulin regimens ([@b42-ce-1-089]). Furthermore, superiority studies showed that Exubera either alone or in combination with oral antidiabetic regimens demonstrated improved glycemic control compared with oral agent monotherapy ([@b17-ce-1-089]; [@b58-ce-1-089]; [@b10-ce-1-089]; [@b23-ce-1-089]; [@b7-ce-1-089]; [@b24-ce-1-089]) ([Table 6](#t6-ce-1-089){ref-type="table"}). Moreover, more patients with type 2 diabetes who were treated with inhaled insulin achieved the ADA and EDPG (IDF Region) targets for HbA~1c~ levels compared with other regimens ([Table 6](#t6-ce-1-089){ref-type="table"}) ([@b11-ce-1-089]).

In all the phase III trials comparing Exubera with subcutaneous insulin, the control groups had two or more insulin injections daily of a soluble insulin, in addition to a basal insulin. However, only one study ([@b68-ce-1-089]) used the same basal insulin in both treatment groups, and none of the studies used a short-acting insulin analog.

Patient satisfaction
--------------------

Eight clinical trials evaluated treatment satisfaction and quality of life compared with subcutaneous insulin or oral antidiabetic therapy in both patients with type 1 diabetes ([@b30-ce-1-089]; [@b71-ce-1-089],[@b72-ce-1-089]; [@b56-ce-1-089]) and type 2 diabetes ([@b63-ce-1-089], [@b64-ce-1-089]; [@b14-ce-1-089]; [@b73-ce-1-089], [@b74-ce-1-089],[@b75-ce-1-089]; [@b42-ce-1-089]) ([Table 7](#t7-ce-1-089){ref-type="table"}).

In general, inhaled insulin had a greater acceptance relating to convenience and ease of use. For obvious practical reasons, these studies were unblinded to their intervention which could potentially affect the outcomes. Furthermore, in these studies patients used syringes and standard needles which are less convenient and more painful than pen-injector devices. The majority of these studies were conducted in the USA, where insulin pen-injector devices are not approved. Therefore, further studies are required to compare treatment satisfaction with inhaled insulin versus pen-injector devices. Patient satisfaction was assessed using a self-administered satisfaction questionnaire. The Patient Satisfaction with Insulin Therapy (PSIT) questionnaire was developed by the manufacturer of Exubera to assess novel forms of insulin delivery such as inhaled insulin ([@b12-ce-1-089]) and was used in phase II studies ([@b30-ce-1-089]; [@b14-ce-1-089]). The self-administered Diabetes Quality of Life and Treatment Satisfaction Questionnaire was independently developed by Phase V Technologies and was used for all phase III studies.

A pooled analysis of the patient satisfaction data from the two 12-week parent studies in patients with type 1 diabetes (n=70) or type 2 diabetes (n=51) receiving Exubera or subcutaneous insulin and 1-year extension studies was performed ([@b59-ce-1-089]). Of the patients who received Exubera, 85% (51 of 60) chose to continue treatment compared with 21% (13 of 61) of patients receiving subcutaneous insulin. In addition, 75% (46 of 61) of patients switched from subcutaneous insulin to Exubera compared with 13% (8 of 60) switching from Exubera to subcutaneous insulin. At 1 year, greater improvements in patient satisfaction were observed in the Exubera group compared with the subcutaneous group for overall satisfaction (37.9% vs 3.1%; *P*\<0.01) and ease of use (43.2% vs −0.9%; *P*\<0.01). However, it should be noted that the sample size at 1 year was greater for the Exubera group compared with the subcutaneous insulin group (95 patients vs 17 patients, respectively) because most of the patients originally in the subcutaneous insulin group switched to Exubera therapy during the study. Patients who switched from inhaled insulin to subcutaneous insulin showed a trend towards worsening satisfaction scores.

In addition, a study of theoretical treatment choices in 779 patients with type 2 diabetes failing to achieve target glycemic control on diet and/or oral antidiabetic therapy demonstrated that patients offered insulin as a treatment option significantly increased the proportion of patients who would theoretically choose insulin ([@b29-ce-1-089]).

Hypoglycemia
------------

Overall evidence indicates that the total number of hypoglycemic episodes with inhaled insulin and subcutaneous insulin is similar, with no increase in the incidence or severity.

Two 6-month studies demonstrated that the risk of overall hypoglycemia was lower in the Exubera group compared with the subcutaneous insulin group for patients with type 1 diabetes (8.6 vs 9 events/subject month; risk ratio 0.96) ([@b56-ce-1-089]) and type 2 diabetes (1.4 vs 1.57 events/subject month; risk ratio 0.89) ([@b42-ce-1-089]). One 3-month study in patients with type 2 diabetes reported a higher rate of hypoglycemic epidodes with Exubera (1.3 events/patient-month) which was not surprising as Exubera was compared with oral antidiabetic therapy alone (0.1 events/patient-month) ([@b58-ce-1-089]). However, a 3-month study in patients with type 1 diabetes reported a higher rate of hypoglycemia with Exubera (6.8 events/subject-month) compared with subcutaneous short-acting insulin (5.5 events/subject-month) ([@b25-ce-1-089]). The incidence of severe hypoglycemic events was low and not significantly different in patients receiving either Exubera or subcutaneous insulin in patients with type 1 diabetes (5.5 events/100 subject months vs 4.7 events/100 subject months) ([@b56-ce-1-089]) or in patients with type 2 diabetes (0.5 events/100 subject months vs 0.1 events/100 subject months, respectively) ([@b42-ce-1-089]).

Weight gain
-----------

Insulin therapy is often associated with weight gain, particularly in patients with type 2 diabetes. Two 6-month studies have reported that treatment with Exubera was not associated with a significant weight gain ([@b42-ce-1-089]; [@b56-ce-1-089]). In patients with type 2 diabetes treated with Exubera, mean body weight after 24 weeks remained stable at 90.5 kg, compared with a mean increase of 1.4 kg to 90.6 kg in body weight in the subcutaneous treatment group by week 24 ([@b42-ce-1-089]). Similar results occurred in patients with type 1 diabetes, with a smaller increase in body weight at week 24 in Exubera-treated patients compared with those receiving subcutaneous insulin (0.9 kg vs 1.5 kg) ([@b56-ce-1-089]).

Tolerability
------------

Level 2 evidence from two RCTs in patients with type 1 diabetes or type 2 diabetes has demonstrated that Exubera is well tolerated ([@b42-ce-1-089]; [@b56-ce-1-089]). In these two studies, adverse events were comparable between treatment groups. Individuals treated with Exubera may develop an increase in serum insulin antibody levels, although these levels were not associated with a significant clinical change ([@b35-ce-1-089],[@b36-ce-1-089]; [@b28-ce-1-089]). A meta analysis of insulin antibody data from Exubera trials demonstrated that there were no correlations between antibody binding and glycemic control, insulin dose requirements, hypoglycemic events, or pulmonary function ([@b28-ce-1-089]). Furthermore, a 24-week study in patients with type 1 diabetes and results from three phase III trials in patients with type 2 diabetes over a 2-year period provided further evidence that the antibody response did not correlate with pulmonary function changes or changes in glycemic control ([@b19-ce-1-089]; [@b26-ce-1-089]).

There have been some concerns regarding the safety of inhaled preparations and whether they compromise lung capacity or damage lung tissue with long-term use.

Mild to moderate cough was more frequent in the inhaled insulin group (21--30.9% of Exubera-treated patients vs 2--7.8% of subcutaneous insulin-treated patients) and decreased with increased exposure. Mean changes in pulmonary function were comparable between patients treated with subcutaneous insulin and Exubera-treated patients ([@b42-ce-1-089]; [@b56-ce-1-089]) except for a greater decrease in carbon monoxide diffusing capacity (DL~co~) in the Exubera group in patients with type 1 diabetes ([@b56-ce-1-089]). This decrease was not associated with any significant clinical or laboratory change.

Evidence in abstract form is available from open-label, 24-week studies which were extended with the objective of assessing pulmonary safety after long-term use of Exubera. A pooled analysis of two 1-year open-label studies involving 627 patients with type 2 diabetes showed that patients who added Exubera to their treatment regimen experienced no clinically important effect on pulmonary function compared with patients treated with oral agents alone ([@b7-ce-1-089]). This study was further extended to 104 weeks and demonstrated that the treatment group differences in pulmonary function as assessed by forced expiratory volume in 1 s (FEV~1~) and DL~co~ were small, not clinically relevant, and did not progress over the 2-year study period ([@b24-ce-1-089]). Furthermore, the treatment differences in pulmonary function reversed after discontinuation of Exubera during the washout phase (week +12 after 104 weeks of therapy) ([@b24-ce-1-089]). An additional analysis of 4-year Exubera data further supported these findings in patients with type 1 or type 2 diabetes ([@b66-ce-1-089],[@b67-ce-1-089]).

Resource utilization
====================

There is no published evidence of the cost effectiveness of Exubera, and no decision has yet been reached on its unit cost. Greater amounts of inhaled insulin are required to produce similar efficacy to injectable formulations because of the reduced bioavailability by this route. Therefore, acquisition costs may be higher for all inhaled insulin delivery systems due to the amount of "wastage." However, it is important to consider the relatively small contribution drug therapy makes to the overall cost of managing diabetes, and the proportionately greater costs of illness and its complications that may be offset if the disease is managed effectively.

Complications of diabetes such as blindness, heart disease, and kidney failure place a huge burden on healthcare services. The IDF estimate that diabetes accounts for between 5 and 10% of a nation's health budget. Moreover, the European Cost Of Diabetes in Europe -- type 2 (CODE-2) study estimated that three times the healthcare resources are spent on treating diabetes complications compared with that spent on controlling diabetes before the onset of complications. This study estimated that the average yearly cost per patient was €2834. Of these costs, hospitalizations accounted for the greatest proportion (55%, range 30--65%) totalling €15.9 billion. In contrast, drug costs for managing type 2 diabetes were relatively low, with antidiabetic drugs and insulin accounting for only 7% of the total healthcare costs for type 2 diabetes ([@b45-ce-1-089]). Therefore, the human and economic costs of diabetes could be reduced by preventing the onset of these complications.

There is strong evidence that good glycemic control with intensive insulin therapy can substantially reduce the risk of and slow the progression of these complications ([@b22-ce-1-089]; [@b52-ce-1-089]; [@b78-ce-1-089]). Studies have shown that HbA~1c~ levels are directly linked to healthcare costs with even a 1% increase in HbA~1c~ levels increasing healthcare costs ([@b31-ce-1-089]; [@b32-ce-1-089]; [@b20-ce-1-089]). Therefore, it would be expected that noncompliance with insulin therapy would lead to poor glycemic control and thereby have an adverse impact on the development of diabetes complications and increase healthcare costs. This highlights the need for alternative therapies for the treatment of diabetes which improve patient adherence and hence glycemic control. Controlling blood glucose should have a beneficial effect on costs, but in order to determine Exubera's place in therapy, comparisons with other inhaled devices and additional patient preference data are needed.

Patient group/population
========================

Level 2 evidence demonstrates the safety and efficacy of Exubera in patients with type 1 and type 2 diabetes who are otherwise healthy, suggesting that it could have a role in the general treatment of patients with uncomplicated disease. Evidence with inhaled insulin is limited in patients with concomitant diseases. Key factors which may influence the efficiency of inhaled insulin delivery include the patients' age (i.e. pediatric and elderly), ability to operate the device, smoking, asthma, exercise, and the presence of lung disease such as chronic obstructive pulmonary disease or chronic bronchitis. Limited evidence from a small number of studies with AERx insulin Diabetes Management System (iDMS) in smokers, patients with asthma, and the elderly is available, some of which may be applicable to Exubera. However, stronger evidence is required to clearly establish the efficacy and safety of Exubera in these patient groups.

Smoking
-------

Smoking appears to greatly enhance insulin absorption by increasing the permeability of the alveolar--capillary barrier ([@b44-ce-1-089]). In a randomized crossover study 27 nondiabetic smokers and 16 nonsmokers received relatively low single doses of 33.8 IU inhaled insulin AERx iDMS ([@b40-ce-1-089]). Absorption of inhaled insulin was significantly greater in smokers with a higher area under the curve (AUC~(0--6\ h)~), *C*~max~ and *t*~max~.

The effects of smoking cessation and resumption on the absorption of Exubera have also been investigated. Two randomized, crossover studies demonstrated that Exubera absorption was two- to three-fold greater in smokers compared with nonsmokers prior to cessation of smoking ([@b62-ce-1-089]; [@b8-ce-1-089]). These studies also showed that the absorption of Exubera decreases during nonsmoking periods and subsequently increases once smoking is resumed ([@b62-ce-1-089]; [@b8-ce-1-089]).

Asthma
------

Individuals with asthma have altered pulmonary function. Therefore, the absorption of inhaled insulin may be affected and the airways of asthmatics may develop a hypersensitivity reaction. An open-label, parallel-group study examined the effects of inhaled insulin (AERx iDMS) on pulmonary function in 17 asthmatic nondiabetic subjects compared with 28 healthy individuals ([@b37-ce-1-089]). The pharmacokinetics and pharmacodynamics of inhaled insulin were also determined. Asthmatic subjects absorbed less insulin than healthy subjects \[insulin AUC~(0--360\ min)~ 1.45 × 10^6^ pmol/min per kg healthy volunteers vs 1.07 × 10^6^ pmol/min per kg asthmatic patients (*P*=0.013)\]. These results suggest that diabetic patients with asthma may need to inhale more insulin than patients with normal respiratory function in order to achieve similar glycemic control.

Age
---

Convenience and ease of use of the Exubera inhaler should be studied in elderly patients with diabetes because the device may have limitations with regards to dexterity, and elderly patients' ability to breathe deeply may be compromised.

It is also necessary to conduct pharmacokinetic studies with Exubera in elderly patients with diabetes to determine the effect of lung aging on the bioavailability of inhaled insulin ([@b9-ce-1-089]). An open-label trial investigating the pharmacokinetics and pharmacodynamics of inhaled insulin (AERx iDMS) demonstrated that the intrasubject variability in elderly patients (≥65 years) was similar to that for young patients (18--45 years) with a comparable pharmacokinetic profile ([@b38-ce-1-089]). However, glucose reduction was significantly less in elderly patients and the authors suggested that elderly diabetic patients may need to inhale more insulin to achieve similar glycemic control.

Furthermore, a trial comparing the pharmacokinetics and pharmacodynamics of Exubera with subcutaneous insulin in elderly patients (mean age 72 years) demonstrated that Exubera is absorbed more rapidly and has a similar or better intrasubject variability than subcutaneous insulin ([@b39-ce-1-089]).

There are insufficient studies to be able to judge utility in elderly patients. Further well-designed studies are required to investigate the effects on insulin absorption and hence the dosage requirements in these patient groups.

Outcomes summary
================

Glycemic control with Exubera inhaled insulin before meals in conjunction with an injected basal insulin is comparable to that in patients receiving multiple daily injections, with no difference in the incidence of hypoglycemia or weight gain.

A major benefit of Exubera in comparison to subcutaneous insulin appears to be the improvement in patient treatment satisfaction which is presumed to be related to its ease of use, leading to better adherence to treatment. However, there is limited evidence to show the effects of long-term Exubera treatment on pulmonary function.

In summary, current evidence suggests that Exubera is an alternative to short-acting subcutaneous insulin therapy providing a further choice for the treatment of patients with type 1 or type 2 diabetes. However, the availability of inhaled insulin would not mean an end to injections, as patients with type 1 diabetes, and many patients with type 2 diabetes, would still require daily injections of basal insulin. Exubera may lead to earlier introduction of insulin therapy in type 2 diabetes based on improved patient acceptance and improved glycemic control and may eliminate the need for mealtime insulin injections in diabetic patients requiring insulin therapy. There is also limited evidence available for the efficacy and safety in patient groups with compromised lung capacity (e.g. smokers, asthmatics). The improved acceptability of Exubera translating into better diabetes control may have a substantial impact on the burden of disease. Further studies are essential to determine Exubera's place in therapy compared with other inhaled insulin delivery systems currently in development.

###### 

Evidence base included in the review

                                                                 **Number of records**                       
  -------------------------------------------------------------- ------------------------------------------- ----
  Initial search                                                 206                                         35
    records excluded                                             195                                         24
    records included                                             11                                          11
  Additional studies identified                                  0                                           15
    records excluded                                             0                                           4
    records included                                             0                                           11
  Search update, new records                                     12                                          14
    records excluded                                             9                                           11
    records included                                             3                                           3
  Level 1 clinical evidence (systematic review, meta analysis)   1                                           0
  Level 2 clinical evidence (RCT)                                11                                          25
  Level ≥3 clinical evidence                                     2                                           0
    trials other than RCT                                        1[a](#tfn1-ce-1-089){ref-type="table-fn"}   0
    case reports                                                 0                                           0
    pharmacokinetic review                                       1[b](#tfn2-ce-1-089){ref-type="table-fn"}   0
  Economic evidence                                              0                                           0

[@b28-ce-1-089].

[@b54-ce-1-089].

For definitions of levels of evidence, see Editorial Information on inside back cover. RCT, randomized controlled trial.

###### 

Commonly used human and analog insulins (adapted from [@b4-ce-1-089])

  -------------------------------------------------------------
  **Rapid-acting insulin analogs**
  Insulin lispro (Humalog^®^)
  Insulin aspart analog (Novolog^®^ USA; NovoRapid^®^ Europe)
  Insulin glulisine (Apidra^™^)
  **Short-acting insulin**
  Human insulin (Humulin R^®^/Novolin R^®^)
  **Intermediate-acting insulin**
  Human NPH (Humulin N^®^/Novolin N^®^)
  Lente
  **Long-acting insulin**
  Insulin glargine analog (Lantus^®^)
  Human ultralente (Humulin U Ultralente^®^)
  Insulin detemir (Levemir^®^) -- not yet approved in the USA
  -------------------------------------------------------------

###### 

Oral antidiabetic medications used for the treatment of type 2 diabetes

  **Class and mechanism of action**                                                                                                    **Drug**
  ------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------
  **Biguanides**                                                                                                                       
  Reduce hepatic glucose production                                                                                                    Metformin
  **Insulin secretagogs (sulfonylureas)**                                                                                              
  Stimulate the islet β cells of the pancreas to produce more insulin                                                                  
    first generation                                                                                                                   Chlorpropamide, tolazamide
    second generation                                                                                                                  Glibenclamide (glyburide), glipizide, glimepiride, gliclazide, gliquidone
  **Rapid-acting insulin secretagogs (meglitinides)**                                                                                  
  Stimulate glucose-mediated insulin secretion                                                                                         Nateglinide, repaglinide
  α**-glucosidase inhibitors**                                                                                                         
  Delay digestion and absorption of intestinal carbohydrate                                                                            Acarbose, miglitol
  **Thiazolidinediones (glitazones)**                                                                                                  
  Peroxisome proliferator-activated receptor-γ agonists: insulin sensitizer improving insulin action and reducing insulin resistance   Rosiglitazone, pioglitazone

###### 

Inhaled insulin products: delivery system and trial phase

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Inhaled insulin system**                          **Manufacturer**                                       **Delivery system**                                                                                                           **Phase**
  --------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------
  Exubera^®^                                          Pfizer; Sanofi-Aventis Group and Nektar Therapeutics   Fine dry-powder insulin\                                                                                                      Phase III\
                                                                                                             Air-assisted mechanism disperses the powder from single-dose blisters into a respirable cloud captured in a holding chamber   Filed for approval in Europe Recommended for approval in USA

  AERx^®^ insulin Diabetes Management System (iDMS)   Aradigm and Novo Nordisk                               Aqueous mist inhaler\                                                                                                         Phase III
                                                                                                             Single-use insulin strips with a hand-held, breath-activated, microprocessor-controlled device                                

  Advanced Inhalation Research (AIR) System           Alkermes and Eli Lilly & Company                       Breath-activated dry-powder inhaler                                                                                           Entering phase III

  Technosphere Insulin System                         MannKind Corporation                                   Proprietary dry-powder technosphere formulation\                                                                              Phase III
                                                                                                             Inhaled using MedTone^®^ inhaler                                                                                              

  Aerodose^™^                                         Aerogen and Disetronic Medical Systems                 Liquid insulin formulation (Humalin I^™^ 500 units)\                                                                          Phase II
                                                                                                             Aerosol delivered by a breath-activated delivery device                                                                       

  Inhaled insulin                                     Kos Pharmaceuticals Inc.                               Dry crystals propellant inhaler                                                                                               Phase II

  Bio-Air                                             BioSante Pharmaceuticals                               Coated dry particles                                                                                                          Preclinical
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Level 2 evidence of blood glucose control in patients with type 1 diabetes achieved with Exubera compared with conventional insulin regimens. Both studies were open-label, randomized, multicenter design lasting 24 weeks

  **Study**                                                                     **Treatment group**                                                         **Outcome**   
  ----------------------------------------------------------------------------- --------------------------------------------------------------------------- ------------- ------
  [@b68-ce-1-089]                                                               Exubera (premeal) plus morning and evening NPH insulin (n=163)              0.3           23.3
  Regular s.c. insulin (premeal) plus morning and evening NPH insulin (n=165)   0.1                                                                         22            
  [@b56-ce-1-089]                                                               Exubera (premeal) plus a single bedtime ultralente s.c. injection (n=170)   0.2           15.9
  Two to three s.c. injections of regular and NPH insulin (n=164)               0.4                                                                         15.5          

s.c., subcutaneous.

###### 

Level 2 evidence of blood glucose control in patients with type 2 diabetes achieved with Exubera compared with conventional insulin regimens. All studies were open-label, randomized, parallel-group, multicenter design

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                                                                **Treatment group**                                         **Study design**                                                                                                                  **Outcome**              
  ------------------------------------------------------------------------ ----------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ----------------- ------ ------
  [@b42-ce-1-089]                                                          Exubera (premeal) plus bedtime dose of ultralente (n=149)   24 weeks; patients previously treated with insulin                                                                                0.7               46.9   28.7

  ≥2 daily injections of s.c. insulin (mixed regular/NPH insulin; n=150)                                                               0.6                                                                                                                               31.7              17.2   

  [@b58-ce-1-089]; [@b17-ce-1-089]                                         Exubera (premeal) monotherapy (n=105)                       12 weeks; patients failing on combination oral antidiabetic agents (sulfonylurea or repaglinide, plus metformin or a glitazone)   1.4               16.7   12.2

  Exubera plus existing oral antidiabetic medication (n=102)                                                                           1.9                                                                                                                               32                7.8    

  Continued oral antidiabetic medication (n=102)                                                                                       0.2                                                                                                                               1                 0      

  [@b10-ce-1-089]; [@b23-ce-1-089]                                         Exubera (premeal) monotherapy (n=76)                        12 weeks; patients failing on diet and exercise alone                                                                             2.3               44     28

  Rosiglitazone 4 mg twice daily (n=69)                                                                                                1.4                                                                                                                               17.9              7.5    

  [@b7-ce-1-089]                                                           Adjunctive Exubera (n=471)                                  Open-label, 24 weeks extended to 52 weeks; patients poorly controlled by metformin or sulfonylurea (HbA~1c~ ≥8%)                  2.2% (week 24)\   ND     ND
                                                                                                                                                                                                                                                                         2% (week 52)             

  Additional oral antidiabetic (metformin or glibenclamide) (n=441)                                                                    2.2% (week 24)\                                                                                                                   ND                ND     
                                                                                                                                       1.8% (week 52)                                                                                                                                             

  [@b24-ce-1-089]                                                          Adjunctive Exubera (n=471)                                  24 weeks, extended to 104 weeks; patients poorly controlled by metformin or sulfonylurea (HbA~1c~ ≥8%)                            1.9%              ND     ND

  Additional oral antidiabetic (metformin or glibenclamide) (n=441)                                                                    1.5%                                                                                                                              ND                ND     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADA, American Diabetes Association; EDPG, European Diabetes Policy Group; ND, data not provided; s.c., subcutaneous.

###### 

Level 2 evidence demonstrating patient satisfaction and quality of life ratings in patients treated with Exubera compared with subcutaneous insulin or oral antidiabetic agents

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Reference**                      **Treatment group**                                              **Study design**                                                                                                                                                                                                                                                      **Outcomes**
  ---------------------------------- ---------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Type 1 diabetes**                                                                                                                                                                                                                                                                                                                                                       

  [@b30-ce-1-089]                    Exubera (premeal) plus bedtime dose of ultralente (n=35)\        Open label; 12 weeks; PSIT questionnaire at baseline and week 12                                                                                                                                                                                                      Overall satisfaction was significantly greater with Exubera than with s.c. insulin (35.1% vs 10.6%; *P*\<0.01)\
                                     s.c. insulin (n=34)                                                                                                                                                                                                                                                                                                                    Improved convenience/ease of use with Exubera compared with s.c. insulin (41.3% vs 11.2%; *P*\<0.01)

  [@b56-ce-1-089];\                  Exubera (premeal) plus bedtime dose of ultralente (n=170)\       Open label; parallel group; 24 weeks; self-administered Diabetes QOL and Treatment Satisfaction Questionnaire at weeks −4, −1, 6, 12, 20, and 24                                                                                                                      Mean overall satisfaction score improved significantly for the Exubera group (*P*\<0.001) and decreased significantly with s.c. insulin (*P*\<0.05) (no scores given)\
  [@b71-ce-1-089];\                  s.c. insulin (n=164)                                                                                                                                                                                                                                                                                                                   Overall QOL scale showed more favorable improvements for the Exubera group versus the s.c. insulin group (*P*\<0.05)
  [@b70-ce-1-089]                                                                                                                                                                                                                                                                                                                                                           

  [@b72-ce-1-089]                    Exubera (premeal) plus NPH insulin twice daily (n=162)\          QOL and satisfaction questionnaire completed at baseline and 6, 12, 20, and 24 weeks                                                                                                                                                                                  Overall satisfaction score improved substantially more for Exubera (from 62.1 to 74.5) compared with regular insulin (from 62.8 to 64.3) (*P*\<0.0001)\
                                     Regular insulin (premeal) plus NPH insulin twice daily (n=165)                                                                                                                                                                                                                                                                         The overall QOL scale and subscales of behavioral and emotional control, general and hyperglycemic symptom distress, overall cognition, mental acuity, and awareness improved more favorably with Exubera compared with regular insulin (all *P*\<0.01--0.05)

  **Type 2 diabetes**                                                                                                                                                                                                                                                                                                                                                       

  [@b14-ce-1-089]                    Exubera (premeal) plus bedtime dose of ultralente (n=26)\        Open label; 12 weeks; PSIT questionnaire                                                                                                                                                                                                                              Overall satisfaction was significantly greater with Exubera than with s.c. insulin (31% vs 13%; *P*\<0.05)\
                                     s.c. insulin (n=25)                                                                                                                                                                                                                                                                                                                    Improvements in overall satisfaction were positively correlated with improvements in HbA~1c~ (r=0.30; *P*\<0.05)

  [@b63-ce-1-089]                    Exubera (premeal) monotherapy\                                   309 patients suboptimally controlled on a sulfonylurea plus either metformin or a thiazolidinedione\                                                                                                                                                                  Proportion of patients receiving Exubera monotherapy or Exubera in combination with oral antidiabetics who preferred the inhaler to their previous combination of oral antidiabetic agents for better glucose control (92%), ease of dose adjustment (79%), overall preference (74%), feeling better about themselves (74%)\
                                     Remain on current oral antidiabetic\                             Patient satisfaction questionnaires completed at baseline and 6 and 12 weeks after randomization                                                                                                                                                                      Patients preferred oral agents for use in public (81%), convenience (69%), ease (63%), and flexibility (59%)
                                     Exubera (premeal) plus current oral antidiabetic                                                                                                                                                                                                                                                                                       

  [@b74-ce-1-089],[@b75-ce-1-089]    Exubera (premeal) (n=222)\                                       24 weeks; patients poorly controlled on sulfonylurea; randomization stratified according to baseline HbA~1c~ levels (low=8--9.5%; high=\>9.5--12%); self-administered questionnaires were completed at baseline (week 0) and at weeks 10, 18, 24, and exit            Improvements in HbA~1c~ were positively correlated with improvements in overall satisfaction (r=0.254; *P*\<0.0001)\
                                     Metformin (n=201)                                                                                                                                                                                                                                                                                                                      Overall QOL improved similarly for Exubera (0.24±0.09, *P*=0.01) and metformin (0.21±0.11, *P*=0.06)\
                                                                                                                                                                                                                                                                                                                                                                            Overall satisfaction (scaled 1--100) substantially improved for both Exubera (from 62.1 to 76.1, *P*=0.0001) and metformin (from 63.1 to 74.1, *P*=0.0001)\
                                                                                                                                                                                                                                                                                                                                                                            High HbA~1c~ stratum: overall satisfaction was 42% greater for Exubera (from 60.2 to 77.1) than metformin (from 61.2 to 73.2) (*P*=0.02)

  [@b64-ce-1-089]; [@b76-ce-1-089]   Exubera (premeal) (n=239)\                                       24 weeks; patients poorly controlled on metformin monotherapy; randomization stratified according to baseline HbA~1c~ levels (low=8--9.5%; high=\>9.5--12%); self-administered questionnaires were completed at baseline (week 0) and at weeks 10, 18, 24, and exit   High HbA~1c~ stratum: overall QOL score more favorable for Exubera (468±5) vs glibenclamide (454±5) (*P*=0.04)\
                                     Glibenclamide (n=231)                                                                                                                                                                                                                                                                                                                  Low HbA~1c~ stratum: no significant difference in overall QOL score between treatment groups (Exubera 457±4 vs glibenclamide 467±5; *P*=0.08)\
                                                                                                                                                                                                                                                                                                                                                                            Similar improvements in treatment satisfaction for both treatment groups\
                                                                                                                                                                                                                                                                                                                                                                            Improvements in HbA~1c~ were positively correlated with improvements in general perceived health (r=0.11; *P*=0.03), general health status (r=0.12; *P*=0.014), and convenience (r=0.15; *P*=0.003)

  [@b42-ce-1-089]; [@b73-ce-1-089]   Exubera (premeal) plus bedtime dose of ultralente (n=149)\       Open label; parallel group; 24 weeks; self-administered Diabetes QOL and Treatment Satisfaction Questionnaire at baseline and weeks 6,12, 20, and 24                                                                                                                  Mean overall satisfaction score improved significantly for the Exubera group (*P*\<0.0001) and worsened slightly with s.c. insulin (no scores given)\
                                     s.c. insulin (n=150)                                                                                                                                                                                                                                                                                                                   Overall QOL scale showed more favorable improvements for the Exubera group versus the s.c. insulin group (*P*\<0.05)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PSIT, Patient Satisfaction with Insulin Therapy Questionnaire; QOL, quality of life; s.c., subcutaneous.
